Related Experiment Video
Updated: Apr 6, 2026

Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
Activity of daptomycin- and vancomycin-loaded poly-epsilon-caprolactone microparticles against mature staphylococcal
Inês Santos Ferreira1, Ana F Bettencourt1, Lídia M D Gonçalves1
1Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
Abstract:
The aim of the present study was to develop novel daptomycin-loaded poly-epsilon-caprolactone (PCL) microparticles with enhanced antibiofilm activity against mature biofilms of clinically relevant bacteria, methicillin-resistant Staphylococcus aureus (MRSA) and polysaccharide intercellular adhesin-positive Staphylococcus epidermidis. Daptomycin was encapsulated into PCL microparticles by a double emulsion-solvent evaporation method. For comparison purposes, formulations containing vancomycin were also prepared. Particle morphology, size distribution, encapsulation efficiency, surface charge, thermal behavior, and in vitro release were assessed. All formulations exhibited a spherical morphology, micrometer size, and negative surface charge. From a very early time stage, the released concentrations of daptomycin and vancomycin were higher than the minimal inhibitory concentration and continued so up to 72 hours. Daptomycin presented a sustained release profile with increasing concentrations of the drug being released up to 72 hours, whereas the release of vancomycin stabilized at 24 hours. The antibacterial activity of the microparticles was assessed by isothermal microcalorimetry against planktonic and sessile MRSA and S. epidermidis. Regarding planktonic bacteria, daptomycin-loaded PCL microparticles presented the highest antibacterial activity against both strains. Isothermal microcalorimetry also revealed that lower concentrations of daptomycin-loaded microparticles were required to completely inhibit the recovery of mature MRSA and S. epidermidis biofilms. Further characterization of the effect of daptomycin-loaded PCL microparticles on mature biofilms was performed by fluorescence in situ hybridization. Fluorescence in situ hybridization showed an important reduction in MRSA biofilm, whereas S. epidermidis biofilms, although inhibited, were not eradicated. In addition, an important attachment of the microparticles to MRSA and S. epidermidis biofilms was observed. Finally, all formulations proved to be biocompatible with both ISO compliant L929 fibroblasts and human MG63 osteoblast-like cells.
Insights
Novel daptomycin-loaded poly-epsilon-caprolactone (PCL) microparticles show enhanced antibiofilm activity against Staphylococcus aureus and Staphylococcus epidermidis biofilms. These biocompatible microparticles offer sustained drug release and potential for treating persistent bacterial infections.
Area of Science:
- Biomaterials Science
- Drug Delivery Systems
- Infectious Diseases
Background:
- Mature bacterial biofilms pose a significant challenge in treating persistent infections.
- Antibiotic resistance, particularly in strains like methicillin-resistant Staphylococcus aureus (MRSA), necessitates novel therapeutic strategies.
- Developing effective drug delivery systems is crucial for enhancing antimicrobial efficacy against biofilms.
Purpose of the Study:
- To develop daptomycin-loaded poly-epsilon-caprolactone (PCL) microparticles for enhanced antibiofilm activity.
- To evaluate the efficacy of these microparticles against mature biofilms of MRSA and Staphylococcus epidermidis.
- To compare the performance of daptomycin-loaded PCL microparticles with vancomycin formulations.
Main Methods:
- Daptomycin was encapsulated into PCL microparticles using a double emulsion-solvent evaporation method.
- Characterization included particle morphology, size, encapsulation efficiency, surface charge, thermal behavior, and in vitro drug release kinetics.
- Antibacterial activity against planktonic and sessile bacteria, as well as mature biofilms, was assessed using isothermal microcalorimetry and fluorescence in situ hybridization.
- Biocompatibility was evaluated using L929 fibroblasts and MG63 osteoblast-like cells.
Main Results:
- Daptomycin-loaded PCL microparticles exhibited sustained release of the drug above the minimal inhibitory concentration for up to 72 hours.
- These microparticles demonstrated superior antibacterial activity against planktonic MRSA and S. epidermidis compared to vancomycin formulations.
- Significant reduction in MRSA biofilms was observed, with inhibition of S. epidermidis biofilms, and notable microparticle attachment to biofilms.
- All tested formulations were found to be biocompatible with relevant cell lines.
Conclusions:
- Daptomycin-loaded PCL microparticles represent a promising strategy for combating MRSA and S. epidermidis biofilms.
- The sustained release and enhanced antibiofilm activity of these microparticles offer a potential therapeutic advantage.
- Further investigation into their clinical application for treating biofilm-associated infections is warranted.
More Related Videos
06:36Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds
Published on: September 8, 2021
07:32Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis
Antimicrobial Effectiveness